The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
